Xilio Therapeutics, Inc. Financials
This page shows Xilio Therapeutics, Inc. (XLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Xilio Therapeutics, Inc. has an operating margin of -95.9%, meaning the company retains $-96 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -955.0% the prior year.
Xilio Therapeutics, Inc.'s revenue surged 589.9% year-over-year to $43.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Xilio Therapeutics, Inc. has a moderate D/E ratio of 3.39. This balance of debt and equity financing earns a leverage score of 33/100.
Xilio Therapeutics, Inc.'s current ratio of 2.58 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.
While Xilio Therapeutics, Inc. generated -$5.0M in operating cash flow, capex of $518K consumed most of it, leaving -$5.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Xilio Therapeutics, Inc. generates a -165.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -330.9% the prior year.
Xilio Therapeutics, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Xilio Therapeutics, Inc. generates $0.09 in operating cash flow (-$5.0M OCF vs -$58.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Xilio Therapeutics, Inc. generated $43.8M in revenue in fiscal year 2025. This represents an increase of 589.9% from the prior year.
Xilio Therapeutics, Inc.'s EBITDA was -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.4% from the prior year.
Xilio Therapeutics, Inc. reported -$58.2M in net income in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Xilio Therapeutics, Inc. earned $-4.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 284.4% from the prior year.
Cash & Balance Sheet
Xilio Therapeutics, Inc. generated -$5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.1% from the prior year.
Xilio Therapeutics, Inc. held $137.5M in cash against $0 in long-term debt as of fiscal year 2025.
Xilio Therapeutics, Inc. had 6M shares outstanding in fiscal year 2025. This represents a decrease of 87.4% from the prior year.
Margins & Returns
Xilio Therapeutics, Inc.'s operating margin was -95.9% in fiscal year 2025, reflecting core business profitability. This is up 859.0 percentage points from the prior year.
Xilio Therapeutics, Inc.'s net profit margin was -133.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 785.0 percentage points from the prior year.
Xilio Therapeutics, Inc.'s ROE was -165.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 165.8 percentage points from the prior year.
Capital Allocation
Xilio Therapeutics, Inc. invested $56.0M in research and development in fiscal year 2025. This represents an increase of 36.0% from the prior year.
Xilio Therapeutics, Inc. invested $518K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1338.9% from the prior year.
XLO Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.1M+135.8% | $8.1M+175.9% | $2.9M | N/A | $2.3M-4.0% | $2.4M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $14.3M-6.6% | $15.3M+85.5% | $8.3M | N/A | $10.8M-4.1% | $11.2M+7.8% | $10.4M | N/A |
| SG&A Expenses | $6.7M-6.3% | $7.1M-16.4% | $8.5M | N/A | $6.3M+8.5% | $5.8M-5.3% | $6.1M | N/A |
| Operating Income | -$1.9M+86.6% | -$14.4M-3.7% | -$13.9M | N/A | -$14.8M-0.4% | -$14.7M+15.9% | -$17.5M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$16.3M-2.8% | -$15.8M-19.4% | -$13.3M | N/A | -$14.0M-0.7% | -$13.9M+19.1% | -$17.2M | N/A |
| EPS (Diluted) | $-0.11+31.3% | $-0.16+11.1% | $-0.18 | N/A | $-0.22+8.3% | $-0.24+61.3% | $-0.62 | N/A |
XLO Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $133.7M-0.1% | $133.8M+29.0% | $103.7M+45.9% | $71.1M-4.8% | $74.7M-16.9% | $89.9M+8.8% | $82.6M+35.6% | $60.9M |
| Current Assets | $124.1M+0.3% | $123.7M+32.7% | $93.2M+54.7% | $60.2M-4.9% | $63.3M-18.8% | $78.0M+12.8% | $69.2M+43.8% | $48.1M |
| Cash & Equivalents | $103.8M-14.6% | $121.6M+36.5% | $89.1M+61.1% | $55.3M-9.7% | $61.3M-18.3% | $74.9M+120.6% | $34.0M-24.0% | $44.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $141.8M+11.9% | $126.7M+36.3% | $93.0M+73.9% | $53.5M-0.4% | $53.7M-4.9% | $56.5M-0.7% | $56.8M+135.9% | $24.1M |
| Current Liabilities | $56.4M+5.9% | $53.3M+11.8% | $47.6M+74.7% | $27.3M-28.3% | $38.0M-1.6% | $38.6M+22.4% | $31.6M+97.9% | $16.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$8.1M-214.5% | $7.1M-33.9% | $10.7M-39.2% | $17.6M-16.1% | $21.0M-37.2% | $33.4M+29.7% | $25.8M-30.0% | $36.8M |
| Retained Earnings | -$429.1M-3.9% | -$412.9M-4.0% | -$397.0M-3.5% | -$383.8M-3.5% | -$370.7M-3.9% | -$356.6M-4.1% | -$342.7M-5.3% | -$325.5M |
XLO Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.5M-20.8% | -$14.5M-150.0% | $29.0M+304.7% | -$14.2M-3.5% | -$13.7M-168.5% | $20.0M+290.0% | -$10.5M+21.8% | -$13.4M |
| Capital Expenditures | $0-100.0% | $401K+1722.7% | $22K+266.7% | $6K-33.3% | $9K | N/A | N/A | $0 |
| Free Cash Flow | -$17.5M-17.6% | -$14.9M-151.4% | $29.0M+304.4% | -$14.2M-3.5% | -$13.7M | N/A | N/A | -$13.4M |
| Investing Cash Flow | $0+100.0% | -$401K-1722.7% | -$22K-266.7% | -$6K+33.3% | -$9K | N/A | N/A | $0 |
| Financing Cash Flow | -$285K-100.6% | $47.4M+880.2% | $4.8M-41.1% | $8.2M+273500.0% | -$3K-100.0% | $20.0M+2000.9% | $954K+158.4% | -$1.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
XLO Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -10.1%+167.6pp | -177.7%+295.0pp | -472.7% | N/A | -652.3%-28.5pp | -623.8% | N/A | N/A |
| Net Margin | -85.4%+110.6pp | -196.0%+256.7pp | -452.7% | N/A | -619.5%-28.7pp | -590.8% | N/A | N/A |
| Return on Equity | N/A | -224.1%-100.2pp | -124.0% | N/A | -66.8%-25.2pp | -41.7%+25.1pp | -66.8% | N/A |
| Return on Assets | -12.2%-0.3pp | -11.8%+1.0pp | -12.8% | N/A | -18.8%-3.3pp | -15.5%+5.3pp | -20.8% | N/A |
| Current Ratio | 2.20-0.1 | 2.32+0.4 | 1.96-0.3 | 2.21+0.5 | 1.67-0.4 | 2.02-0.2 | 2.19-0.8 | 3.02 |
| Debt-to-Equity | -17.52-35.4 | 17.93+9.2 | 8.69+5.7 | 3.04+0.5 | 2.56+0.9 | 1.69-0.5 | 2.21+1.6 | 0.65 |
| FCF Margin | -91.8%+92.3pp | -184.0%-1172.3pp | 988.3% | N/A | -604.5% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Xilio Therapeutics, Inc.'s annual revenue?
Xilio Therapeutics, Inc. (XLO) reported $43.8M in total revenue for fiscal year 2025. This represents a 589.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xilio Therapeutics, Inc.'s revenue growing?
Xilio Therapeutics, Inc. (XLO) revenue grew by 589.9% year-over-year, from $6.3M to $43.8M in fiscal year 2025.
Is Xilio Therapeutics, Inc. profitable?
No, Xilio Therapeutics, Inc. (XLO) reported a net income of -$58.2M in fiscal year 2025, with a net profit margin of -133.1%.
What is Xilio Therapeutics, Inc.'s EBITDA?
Xilio Therapeutics, Inc. (XLO) had EBITDA of -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Xilio Therapeutics, Inc.'s operating margin?
Xilio Therapeutics, Inc. (XLO) had an operating margin of -95.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xilio Therapeutics, Inc.'s net profit margin?
Xilio Therapeutics, Inc. (XLO) had a net profit margin of -133.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xilio Therapeutics, Inc.'s return on equity (ROE)?
Xilio Therapeutics, Inc. (XLO) has a return on equity of -165.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xilio Therapeutics, Inc.'s free cash flow?
Xilio Therapeutics, Inc. (XLO) generated -$5.5M in free cash flow during fiscal year 2025. This represents a 70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Xilio Therapeutics, Inc.'s operating cash flow?
Xilio Therapeutics, Inc. (XLO) generated -$5.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Xilio Therapeutics, Inc.'s total assets?
Xilio Therapeutics, Inc. (XLO) had $154.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Xilio Therapeutics, Inc.'s capital expenditures?
Xilio Therapeutics, Inc. (XLO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Xilio Therapeutics, Inc. spend on research and development?
Xilio Therapeutics, Inc. (XLO) invested $56.0M in research and development during fiscal year 2025.
What is Xilio Therapeutics, Inc.'s current ratio?
Xilio Therapeutics, Inc. (XLO) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.
What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?
Xilio Therapeutics, Inc. (XLO) had a debt-to-equity ratio of 3.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xilio Therapeutics, Inc.'s return on assets (ROA)?
Xilio Therapeutics, Inc. (XLO) had a return on assets of -37.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xilio Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Xilio Therapeutics, Inc. (XLO) had $137.5M in cash against an annual operating cash burn of $5.0M. This gives an estimated cash runway of approximately 331 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Xilio Therapeutics, Inc.'s Piotroski F-Score?
Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xilio Therapeutics, Inc.'s earnings high quality?
Xilio Therapeutics, Inc. (XLO) has an earnings quality ratio of 0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. (XLO) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.